Somahlution is a privately-held development-stage life science company focused on advancing the science of organ and surgical conduit transplantation. Led by a highly experienced team of executives, transplant researchers and surgeons, Somahlution's products and technologies have the potential to profoundly impact the landscape of transplant medicine.
Improvements in the solutions that facilitate organ and surgical conduit preservation are critically needed in transplant medicine, coronary artery bypass and peripheral vascular surgery in order to improve long-term patient outcomes and quality of life. Over 100,000 patients each year are faced with a life threatening need for an organ transplant and are on a waiting list. There are over 1.5 million surgical procedures performed in the United States only that require viable conduits. About 10-25% of implanted conduits fail within a year, requiring additional surgery, resulting in increased morbidity and high healthcare costs. Somahlution's technologies are designed to maintain and enhance the function of donor organs and vascular conduits, and thus reduce post-transplant complications and improve long-term outcomes.
Somahlution's lead product candidates, SOM102, SOM103 and SOMVC001, are currently being prepared for clinical evaluations in heart transplant, in kidney transplant, and Coronary Artery Bypass Graft (CABG) surgical procedures, respectively.